Isatuximab in Combination With Novel Agents in RRMM - Master Protocol
Plasma Cell Myeloma Refractory
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 1/2
- Patients
- 258 (planned)
- Started
- Jan 25, 2021
- Main results expected
- Sep 13, 2027
- Fully finished
- Apr 20, 2028
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Part 1 (dose finding, experimental substudies): Determination of recommended dose of novel agents in combination with isatuximab
Measured over: Through the end of cycle 1 (approximately 6 weeks)
Part 2 (expansion, controlled experimental substudies): VGPR Rate (Rate of Very Good Partial Response Rate or Better)
Measured over: Up to approximately 28 months after the First patient in or scheduled assessment
Part 2 (expansion, independent experimental substudies): Overall Response Rate (ORR) in independent experimental substudies
Measured over: Up to approximately 28 months after the First patient in or scheduled assessment
Changes Tremor has spotted
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT04643002 · record last updated 2026-10-13 · checked 2026-11-09 15:47 UTC